DESIGNING AND OPTIMIZATION OF NAPROXEN SODIUM DEFORMABLE VESICULAR SYSTEMS THROUGH FACTORIAL DESIGN: BOX BEHENKEN MODEL
Objective: The objective of this investigation was to develop and statistically optimize deformable vesicles such as transfersomes and transethosomes of Naproxen sodium by employing 33 factorial design through software Design expert version 12 (Box–Behnken design) for dermal delivery.
Methods: The levels of the drug, phosphatidylcholine and span 80 (independent variables) were varied to study the influence on vesicle size and % entrapment efficiency (dependent variables) of transfersomes and for transethosomes the levels of phosphatidylcholine, ethanol and span 80 were selected as independent variables Second order quadratic polynomial equation, 2D and 3D contour plots represented relationship between variables and desired response. The optimization process were carried out using desirability plots and Point prediction techniques
Results: Results of the present study demonstrated that optimized transfersomes and transethosomes shown vesicle size of 114.91 nm and 102.91 nm respectively while entrapment efficiency of 80.11 % and 86.97% respectively. Both formulations showed high zeta potential values indicating stability of optimized formulation. ANOVA statistical results showed significance difference (P < 0.05).
Conclusion: The results indicated that independent variable plays a crucial role in optimizing a formulation which can be used for further research studies. Present preliminary study data provided a strong evidence that the optimized deformable vesicular formulations through box behenken factorial design can be a potentially useful drug carrier for naproxen sodium dermal delivery with minimum vesicle size and efficient entrapment efficiency.
2. Pandey P and Pancholi S. Nanocarriers: A novel treatment approach for arthritis. Int J Pharm Sci & ResVol 2013;4: 4165-4174.
3. Kumavat S, Chaudhari Y and Borole P. Transfersomes: A promising approach for transdermal drug delivery system. Asian journal of pharmaceutical sciences and research 2013; 3:1-17.
4. Mezei M and Gulasekharam V. Liposomes – a selective drug delivery system for the topical route of administration Lotion dosage form. Life Sci 1980;26:1473–1477.
5. Verma D, Verma S and Blume G. Particle size of liposomes influences dermal delivery of substances into skin. Int J Pharm 2003;258:141–151.
6. Manosroi A, Jantrawut P and Manosroi J. Anti-inflammatory activity of gel containing novel elastic niosomes entrapped with diclofenac diethylammonium. Int J Pharm 2008;360:156–163.
7. G. Cevc. Transfersomes, liposomes and other lipid suspensions on the skin: permeation enhancement, vesicle penetration, and transdermal drug delivery. Crit. Rev. Ther. Drug Carrier Syst1996; 13:257-388.
8. Maghraby G,Williams A, Barry A. Interactions of surfactants (edge activators) and skin penetration enhancers with liposomes. Int. J. Pharm 2004 May 19;276:143-61.
9. E. Touitou, M. Alkabes, N. Dayan. Ethosomes - novel vesicular carriers for enhanced delivery: characterization and skin penetration properties. Pharm. Res 2000; 65:403-18.
10. Elsayed M, Abdallah O, Naggar V and Khalafallah V. Lipid vesicles for skin delivery of drugs: reviewing three decades of research. Int. J. Pharm 2007; 332:1-16.
11. Shaji J and Vinit M, Novel double loaded transferosomes: evidence of superior antiinflammatory efficacy- a comparative study. International Journal of Current Pharmaceutical Research 2014;6:16-25.
12. Shaji J and Bajaj R. Formulation Development of 5-Fluorouracil Transethosomes for Skin Cancer Therapy. International journal of pharmacy and pharmaceutical research 2017; 11: 453-464.
13. Shaji J, Maria Lal. Preparation, optimization and evaluation of transferosomal formulation for enhanced transdermal delivery of a cox-2 inhibitor. Int J Pharm Pharm Sci 2014;6: 467-477.
14. Vyas P, Vyas P, Raval D and Paghdar P, Development of Topical Niosomal Gel of Benzoyl ISRN Nanotechnology 2011, Article ID 503158,1- 6.
15. Sara M. Soliman, Nevine S. Abdelmalak and Omaima N. Novel non-ionic surfactant proniosomes for transdermal delivery of lacidipine: optimization using 23 factorial design and in vivo evaluation in rabbits. Drug Deliv 2016;23:1608–1622.
16. Mohanty D, Rani M and Haque M. Preparation and evaluation of transdermal- naproxen niosomes: formulation optimization to preclinical anti-inflammatory assessment on murine model. Journal of liposome research 2019,1-7.
17. Alima S. Kassema A,Bashaa M , Salama A. Comparative study of liposomes, ethosomes and transfersomes as carriers for enhancing the transdermal delivery of diflunisal: In vitro and in vivo evaluation. International Journal of Pharmaceutics 2019; 30:293–303.
18. Touitou E, Dayan N and Bergelson L. Ethosomes – novel vesicular carriers for enhanced delivery: characterization and skin penetration properties. J Control Release 2000; 65:403–418.
19. Dubey V, Mishra D, Dutta T. Dermal and transdermal delivery of an anti-psoriatic agent via ethanolic liposomes. J Control Release 2007;123:148–154.
20. Ahad A, Aqil M and Kohli K. Enhanced transdermal delivery of an anti-hypertensive agent via nanoethosomes: statistical optimization characterization and pharmacokinetic assessment. Int JPharm 2013; 443:26–38.
21. El Zaafarany GM, Awad GA and Holayel SM. Role of edge activators and surface charge in developing ultradeformable vesicles with enhanced skin delivery. Int J Pharm 2010; 397:164–172.
22. Chen G, D Li, Y Jin, Zhang W and Teng L. Deformable liposomes by reverse-phase evaporation method for an enhanced skin delivery of (þ)- catechin. Drug Dev Ind Pharm 2013; 40: 260-265.
23. Simões SI, Marques CM, Cruz ME, Cevc G and Martins M. The effect of cholate on solubilisation and permeability of simple and protein-loaded phosphatidylcholine/sodium cholate mixed aggregates designed to mediate transdermal delivery of macromolecules. Eur J Pharm Biopharm 2004;58: 509-519.
24. Van den Bergh BA, Wertz PW, Junginger HE and Bouwstra JA. Elasticity of vesicles assessed by electron spin resonance, electron microscopy and extrusion measurements. Int J Pharm 2001;1:13-24.
This work is licensed under a Creative Commons Attribution 4.0 International License.